FY2023 Financial Results
FY2023 Update
3 new drug approvals
from the U.S. FDA
And multiple life-cycle management approvals in FY2023
FY2023 Financial Results
Revenue
¥4,263.8B
+1.5% growth at CER +5.9% growth at AER
FY2023 Financial Results
Core Operating Profit | Core Operating | Reported Operating |
Profit Margin | Profit |
¥1,054.9B 24.7% ¥214.1B
-13.3% change at Constant Exchange Rate (CER) / -11.2% at Actual Exchange Rate (AER) reflects generic impact and increased investment in R&D and data & technology
-56.4% change at Actual Exchange Rate impacted by non-core items
FY2023 Financial Results
Our extensive portfolio of
Growth & Launch Products continued to drive revenue growth.
43%
Share of Total Revenue
+12.8%
Growth at CER
FY2024 Outlook Highlights
50 million doses of dengue vaccine
to be manufactured per year in partnership with Biological E. Ltd.
Accelerating our goal to manufacture 100 million doses per year by 2030
FY2024 Outlook Highlights
Up to 6 potential new therapies
expected in Phase 3 development in FY2024
FY2024 Full-Year Outlook
Continued momentum of Growth & Launch Products expected to mitigate remaining loss of exclusivity headwinds
Core Revenue | Core Operating Profit |
¥4,350.0B | B |
¥1,000.0 |
Management Guidance at CER | |
Core Revenue | Core Operating Profit |
Flat to slightly | Approximately |
declining | 10% decline |
Core EPS
¥431
Core EPS
Mid-10s% decline
This presentation contains forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations. For more information about our use of forward-looking statements, including important cautionary language, see Takeda's FY2023 investor presentation (available at https://www.takeda.com/investors/financial-results/quarterly-results/), which is hereby incorporated by reference. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
CER (Constant Exchange Rate) change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating Reported or Core results for the current period using corresponding exchange rates in the same period of the previous fiscal year.
Core Revenue, Core Operating Profit, Core Operating Profit Margin, Core EPS, CER % Change, Net Debt, Adjusted EBITDA, and Free Cash Flow are Non-IFRS measures, i.e., measures not calculated and presented in accordance with IFRS. See the financial appendix at the end of Takeda's FY2023 investor presentation (available at https://www.takeda.com/investors/financial-results/quarterly-results/ ) for further information about Takeda's Non-IFRS Measures and reconciliations to the most directly comparable measures calculated and presented in accordance with IFRS.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Takeda Pharmaceutical Co. Ltd. published this content on 09 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 May 2024 06:08:10 UTC.